Literature DB >> 14517442

Soluble VEGF receptors.

C Hornig1, H A Weich.   

Abstract

The three human VEGF receptors 1-3 mediate biological signals important for new blood vessel formation and lymphangiogenesis. Soluble VEGF receptors contain all the information necessary for high affinity ligand binding and have been used as experimental tools and regulators in several angiogenic in vitro and in vivo models. Recombinant receptor molecules can be used for specific inhibition of VEGF mediated signal transduction and for blocking tumor angiogenesis by limiting the amount of VEGF secreted from tumor cells or stroma cells. A naturally occurring soluble VEGFR-1 has been discovered in the supernatant from endothelial cells and at present appears to be the key regulator for the availability of VEGF secreted from different cells and tissues. The exact physiological role has not yet been demonstrated.

Entities:  

Year:  1999        PMID: 14517442     DOI: 10.1023/a:1009033017809

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  19 in total

1.  MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

Authors:  Manik Chahal; Yaoxian Xu; David Lesniak; Kathryn Graham; Konrad Famulski; James G Christensen; Manish Aghi; Amanda Jacques; David Murray; Siham Sabri; Bassam Abdulkarim
Journal:  Neuro Oncol       Date:  2010-02-23       Impact factor: 12.300

2.  VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Christopher D Kontos; Brian H Annex; Aleksander S Popel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

3.  A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1.

Authors:  Daniel Menendez; Alberto Inga; Joyce Snipe; Oliver Krysiak; Gilbert Schönfelder; Michael A Resnick
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

4.  Opposing roles for HIF-1α and HIF-2α in the regulation of angiogenesis by mononuclear phagocytes.

Authors:  Tim D Eubank; Julie M Roda; Haowen Liu; Todd O'Neil; Clay B Marsh
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

5.  Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma.

Authors:  Munechika Enjoji; Makoto Nakamuta; Koji Yamaguchi; Satoshi Ohta; Kazuhiro Kotoh; Marie Fukushima; Masami Kuniyoshi; Tomomi Yamada; Masao Tanaka; Hajime Nawata
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

6.  Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients.

Authors:  Jun Li; Han Zhang; Peng Sun; Feng Gu; Zhe-Li Liu
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

Review 7.  Angiogenesis and lymphangiogenesis in corneal transplantation-A review.

Authors:  Wei Zhong; Mario Montana; Samuel M Santosa; Irene D Isjwara; Yu-Hui Huang; Kyu-Yeon Han; Christopher O'Neil; Ashley Wang; Maria Soledad Cortina; Jose de la Cruz; Qiang Zhou; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar
Journal:  Surv Ophthalmol       Date:  2017-12-27       Impact factor: 6.048

Review 8.  A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Christopher D Kontos; Brian H Annex; Aleksander S Popel
Journal:  J Cell Mol Med       Date:  2009-10-16       Impact factor: 5.310

Review 9.  VEGF and imaging of vessels in rheumatoid arthritis.

Authors:  Peter C Taylor
Journal:  Arthritis Res       Date:  2002-05-09

10.  Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.

Authors:  Ewa Robak; Anna Sysa-Jedrzejewska; Tadeusz Robak
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.